Abogen Biosciences signs licensing, option deal with Novartis for ABO2203 mRNA T-cell engager

• Suzhou Abogen Biosciences entered a licensing, option agreement with Novartis to advance RNA-encoded therapeutics.
• Deal grants Novartis an exclusive worldwide license to ABO2203, an mRNA-encoded CD19xCD3 T-cell engager.
• Novartis also secured exclusive options to license additional programs using Abogen’s proprietary RNA platform.
• Abogen will receive USD 575 million upfront.
• Abogen could earn up to about USD 7.2 billion in milestones if all options are exercised, with potential royalties on sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Suzhou Abogen Biosciences Co. Ltd. published the original content used to generate this news brief on October 02, 2026, and is solely responsible for the information contained therein.